AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph at page 16, lines 26-32, as follows:

The compositions containing the present adenoviruses or cocktails thereof can be administered for prophylactic and/or therapeutic treatments of neoplastic disease. In therapeutic application, compositions are administered to a patient already affected by the particular neoplastic disease, in an amount sufficient to cure or at least partially arrest the condition and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose" or "efficacious dose." Amounts effective for this use will depend upon the severity of the condition, the general state of the patient, the route of administration and the potency of the virus. ?

Please amend Table 2 on page 18 by adding the SEQ ID NO column, as follows:

Table 2.

Virus	Mutation	Primer sequences	SEQ ID NO:
ONYX-051	R240A	GTTATTATGAATGTAGCGTTTACTGGCCCC	1
		GGGGCCAGTAAACGCTACATTCATAATAAC	2
ONYX-052	T255A	GTTTTCCTGGCCAATGCCAACCTTATCCTACAC	3
		GTGTAGGATAAGGTTGGCATTGGCCAGGAAAAC	4
ONYX-053	H260A	CCAACCTTATCCTAGCCGGTGTAAGCTTC	5
		GAAGCTTACACCGGCTAGGATAAGGTTGG	6
ONYX-054	C271A	GGGTTTAACAATACCGCCGTGGAAGCCTGG	7
		CCAGGCTTCCACGGCGGTATTGTTAAACCC	8
ONYX-056	R281A	CGATGTAAGGGTTGCGGGCTGTGCCTTTTAC	9
		GTAAAAGGCACAGCCCGCAACCCTTACATCG	10
ONYX-057	G282A	GTAAGGGTTCGGGCCTGTGCCTTTTAC	11
		GTAAAAGGCACAGGCCCGAACCCTTAC	12
ONYX-058	A284A	GTAAGGGTTCGGGGCTGTTCCTTTTACTGCTGCTGGAAGG	13
		CCTTCCAGCAGCAGTAAAAGGAACAGCCCCGAACCCTTAC	14
ONYX-059	F285L	GGTTCGGGGCTGTGCCTTATACTGCTGCTGGAAGGGG	15
		CCCCTTCCAGCAGCAGTATAAGGCACAGCCCCGAACC	16
ONYX-060	C288A	GGGCTGTGCCTTTTACTGCGCCTGGAAGGGGGTGGTGTG	17
		CACACCACCCCCTTCCAGGCGCAGTAAAAGGCACAGCCC	18
ONYX-061	W289F	GCTGTGCCTTTTACTGCTGCTTTAAGGGGGTGGTGTGTCGC	19
		GCGACACACCACCCCCTTAAAGCAGCAGTAAAAGGCACAGC	20
ONYX-062	W289A	GCTGTGCCTTTTACTGCTGCGCGAAGGGGGTGGTGTGTCG	21
		CGACACACCACCCCCTTCGCGCAGCAGTAAAAGGCACAGC	22

ONYX-063	K290A	CTGCTGCTGGGCGGGGGTGGTG	23
		CACCACCCCCGCCCAGCAGCAG	24
ONYX-064	R295A	TGGAAGGGGGTGGTGTGTGCCCCCAAAAGCAGGGCTTC	25
		GAAGCCCTGCTTTTGGGGGCACACACCACCCCCTTCCA	26
ONYX-065	K297A	GGTGGTGTGTCGCCCCGCAAGCAGGGCTTCAATTAAGAAATG	27
		CATTTCTTAATTGAAGCCCTGCTTGCGGGGCGACACACCACC	28
ONYX-066	K303A	CCAAAAGCAGGGCTTCAATTGCGAAATGCCTCTTTGAAGGTG	29
		CACCTTTCAAAGAGGCATTTCGCAATTGAAGCCCTGCTTTTGG	30
ONYX-067	E308A	CTTCAATTAAGAAATGCCTCTTTGCAAGGTGTACCTTGGGTATCC	31
		GGATACCCAAGGTACACCTTGCAAAGAGGCATTTCTTAATTGAAG	32

Please amend Table 2 (cont.) on page 19 by adding the SEQ ID NO column, as follows:

ONYX-068	R309A	TCAATTAAGAAATGCCTCTTTGAAGCGTGTACCTTGGGTATCCTGTC	33
		GACAGGATACCCAAGGTACACGCTTCAAAGAGGCATTTCTTAATTGA	34
ONYX-069	E317A	TACCTTGGGTATCCTGTCTGCGGGTAACTCCAGGGTGCG	35
		CGCACCCTGGAGTTACCCGCAGACAGGATACCCAAGGTA	36
ONYX-070	G318A*	TACCTTGGGTATCCTGTCTGAGGCTACCTCCAGGGTCCGCC	37
		GGCGGACCCTGGAGGTAGCCTCAGACAGGATACCCAAGGTA	38
ONYX-071	G318A-N	TACCTTGGGTATCCTGTCTGAGGCTAACTCCAGGGTGCGCC	39
		GGCGCACCCTGGAGTTAGCCTCAGACAGGATACCCAAGGTA	40
ONYX-080	E421A	CTAAGATATTGCTTGAGCCGGCGAGCATGTCCAAGGTGAAC	41
		GTTCACCTTGGACATGCTCGCCGGCTCAAGCAATATCTTAG	42
ONYX-081	K425A	GAGCCCGAGAGCATGTCCGCGGTGAACCTGAACGGGG	43
		CCCCGTTCAGGTTCACCGCGGACATGCTCTCGGGCTC	44
ONYX-082	D433A	GAACCTGAACGGGGTGTTTGCCATGACCATGAAGATCTGG	45
		CCAGATCTTCATGGTCATGGCAAACACCCCGTTCAGGTTC	46
ONYX-083	K440A	CCATGAAGATCTGGGCGGTGCTGAGGTAC	47
		GTACCTCAGCACCGCCCAGATCTTCATGG	48
ONYX-084	R443A	GGAAGGTGCTGGCGTACGATGAGACC	49
		GGTCTCATCGTACGCCAGCACCTTCC	50
ONYX-085	Y444A	GGAAGGTGCTGAGGGCCGATGAGACCCGC	51
		GCGGGTCTCATCGGCCCTCAGCACCTTCC	52

Table 2, continued

* Onyx-070 had two amino acids changed: Gly 318 to Ala, and Asn 319 to Thr.